← Human Trials & Peer-Reviewed Studies
Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers
Plain-language guide to PMID 12551742 (2003): double-blind randomized controlled trial study of Cholecystokinin (CCK).
Key Facts
- PMID
- 12551742
- Journal
- Progress in neuro-psychopharmacology & biological psychiatry
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Knott V et al. (5 authors)
- DOI
- 10.1016/S0278-5846(02)00350-0
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Cholecystokinin (CCK).
This study investigated the effects of continuous slow infusion of cholecystokinin tetrapeptide (CCK-4), a neuropeptide with panicogenic properties, on functional hemispheric differences, as indexed by quantitative electroencephalographic (EEG) asymmetry and coherence measures.
Who Took Part
By PubMed's age tags, the people studied were teenagers and adults, both men and women.
Twenty-four adult volunteers (15 females and 9 males) were assigned to infusion with either placebo or CCK-4 in a randomized, double-blind, parallel-group design, with EEG being recorded before and during (10 and 40 min) a 60-min infusion period.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.
Because people in this Cholecystokinin (CCK) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Cholecystokinin (CCK).
The comparison arm used a placebo, so changes seen with Cholecystokinin (CCK) could be set against what happens without it.
The Cholecystokinin (CCK) group and the comparison group ran side by side rather than switching.
What Was Measured
This study investigated the effects of continuous slow infusion of cholecystokinin tetrapeptide (CCK-4), a neuropeptide with panicogenic properties, on functional hemispheric differences, as indexed by quantitative electroencephalographic (EEG) asymmetry and coherence measures.
PubMed files the paper under topics including Cholecystokinin, Electroencephalography, Functional Laterality, Panic Disorder and Temporal Lobe.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK).
The publication is from 2003 (Progress in neuro-psychopharmacology & biological psychiatry), a journal based in England.
More context: the Cholecystokinin (CCK) compound page, all human trials.
Our Notes on the Compound
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.